Alzheimer's disease normative cerebrospinal fluid biomarkers validated in pet amyloid-β characterized subjects from the Australian imaging, biomarkers and lifestyle (AIBL) study

Q.X. Li, V.L. Villemagne, J.D. Doecke, A. Rembach, S. Sarros, S. Varghese, A. Mcglade, K.M. Laughton, K.K. Pertile, C.J. Fowler, R.L. Rumble, B.O. Trounson, K. Taddei, S.R. Rainey-Smith, S.M. Laws, J.S. Robertson, L.A. Evered, B. Silbert, K.A. Ellis, C.C. RoweS.L. Macaulay, D. Darby, Ralph Martins, D. Ames, C.L. Masters, S. Collins

    Research output: Contribution to journalArticle

    31 Citations (Scopus)

    Abstract

    Background: The cerebrospinal fluid (CSF) amyloid-β (Aβ)1-42, total-tau (T-tau), and phosphorylated-tau (P-tau181P) profile has been established as a valuable biomarker for Alzheimer's disease (AD). Objective: The current study aimed to determine CSF biomarker cut-points using positron emission tomography (PET) Aβ imaging screened subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, as well as correlate CSF analyte cut-points across a range of PET Aβ amyloid ligands. Methods: Aβ pathology was determined by PET imaging, utilizing 11C-Pittsburgh Compound B, 18F-flutemetamol, or 18Fflorbetapir, in 157 AIBL participants who also underwent CSF collection. Using anINNOTEST assay, cut-points were established (Aβ 1-42 >544 ng/L, T-tau
    Original languageEnglish
    Pages (from-to)175-187
    JournalJournal of Alzheimer's Disease
    Volume48
    Issue number1
    DOIs
    Publication statusPublished - 28 Aug 2015

    Fingerprint Dive into the research topics of 'Alzheimer's disease normative cerebrospinal fluid biomarkers validated in pet amyloid-β characterized subjects from the Australian imaging, biomarkers and lifestyle (AIBL) study'. Together they form a unique fingerprint.

    Cite this